Epigenetic modifications in chronic myeloid leukemia cells through ruxolitinib treatment
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.27744
Abstract: Chronic myeloid leukemia is a clonal malignancy of hematopoietic stem cell that is characterized by the occurrence of t(9;22)(q34;q11.2) translocation, named Philadelphia chromosome. Ruxolitinib is a powerful Janus tyrosine kinase 1 and 2 inhibitor that… read more here.
Keywords: epigenetic modifications; ruxolitinib treatment; cells ruxolitinib; myeloid leukemia ... See more keywords
Recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Sign Up to like & getrecommendations! Published in 2018 at "Hematology"
DOI: 10.1080/10245332.2017.1385192
Abstract: ABSTRACT Objectives: Myelofibrosis (MF) is a severe disease, with decreased life expectancy and heavy symptom burden. Ruxolitinib is the only approved pharmacotherapy for the treatment of MF patients. In Belgium, ruxolitinib is only reimbursed for… read more here.
Keywords: ruxolitinib; ruxolitinib treatment; treatment; myelofibrosis ... See more keywords
Ruxolitinib for the treatment of graft-versus-host disease
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2020.1740592
Abstract: ABSTRACT Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are… read more here.
Keywords: ruxolitinib treatment; treatment; host disease; ruxolitinib ... See more keywords
Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis.
Sign Up to like & getrecommendations! Published in 2017 at "Blood advances"
DOI: 10.1182/bloodadvances.2017007526
Abstract: Optimal salvage therapy for refractory HLH is unknown.In our patient, ruxolitinib treatment led to clinical remission of refractory HLH. read more here.
Keywords: refractory hemophagocytic; ruxolitinib treatment; treatment refractory; hemophagocytic lymphohistiocytosis ... See more keywords
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1117815
Abstract: Patients affected by myelofibrosis (MF) or polycythemia vera (PV) and treated with ruxolitinib are at high risk for severe coronavirus disease 2019. Now a vaccine against the virus SARS-CoV-2, which is responsible for this disease,… read more here.
Keywords: ruxolitinib treatment; response; booster; myelofibrosis polycythemia ... See more keywords
Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of infection in developing countries"
DOI: 10.3855/jidc.15126
Abstract: INTRODUCTION Severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) infection is characterised by a viral phase and a severe pro-inflammatory phase. The inhibition of the JAK/STAT pathway limits the pro-inflammatory state in moderate to severe COVID-19. METHODOLOGY… read more here.
Keywords: ruxolitinib treatment; cov pneumonia; pro inflammatory; ordinal scale ... See more keywords